Moleculin Biotech Inc (MBRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Moleculin Biotech Inc (MBRX) has a cash flow conversion efficiency ratio of -0.358x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.37 Million) by net assets ($15.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MBRX stock market capitalisation for the company's overall valuation and market capitalisation.
Moleculin Biotech Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Moleculin Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Moleculin Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moleculin Biotech Inc ranked by their cash flow conversion efficiency. Explore Moleculin Biotech Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
-0.507x |
|
Sequoia Financial Group Ltd
AU:SEQ
|
0.030x |
|
Haoxin Holdings Limited Class A Ordinary Shares
NASDAQ:HXHX
|
-0.029x |
|
Addentax Group Corp
NASDAQ:ATXG
|
-0.001x |
|
Mears Group plc
LSE:MER
|
0.354x |
|
Lion Energy Ltd
AU:LIO
|
-0.111x |
|
Rare Earth Magnesium Technology Group Holdings Limited
STU:GPS
|
0.016x |
|
Autonomix Medical, Inc. Common Stock
NASDAQ:AMIX
|
-1.121x |
Annual Cash Flow Conversion Efficiency for Moleculin Biotech Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Moleculin Biotech Inc from 2015 to 2025. View current stock price of Moleculin Biotech Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.01 Million | $-22.73 Million | -1.515x | +62.04% |
| 2024-12-31 | $5.98 Million | $-23.86 Million | -3.991x | -331.75% |
| 2023-12-31 | $26.07 Million | $-24.10 Million | -0.924x | -74.55% |
| 2022-12-31 | $52.19 Million | $-27.64 Million | -0.530x | -120.74% |
| 2021-12-31 | $78.99 Million | $-18.95 Million | -0.240x | +75.85% |
| 2020-12-31 | $17.89 Million | $-17.77 Million | -0.993x | +10.06% |
| 2019-12-31 | $15.57 Million | $-17.20 Million | -1.104x | -29.18% |
| 2018-12-31 | $14.27 Million | $-12.20 Million | -0.855x | -99.84% |
| 2017-12-31 | $17.12 Million | $-7.32 Million | -0.428x | -70.01% |
| 2016-12-31 | $14.96 Million | $-3.76 Million | -0.252x | -144.25% |
| 2015-12-31 | $-744.70K | $-423.51K | 0.569x | -- |
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more